MTOR and glycogen storage disease VI: In a non-human primate graft versus host disease model using the transplantation of allogeneic hematopoietic stem cells, concurrent blockade of OX40L with monoclonal antibody (KY1005) and mechanistic target of rapamycin (mTOR) with sirolimus increased Treg cells in the blood and prevented graft rejection [114].